Key insights
- The Centers for Medicare & Medicaid Services (CMS) plans to cut Medicare lab fee reimbursements by up to 15% annually starting January 1, 2027, aiming to align rates with private insurers. This move, which will be phased in gradually until 2029, poses a significant revenue risk to Quest Diagnostics (DGX) and Labcorp (LH), as they derive substantial income from Medicare-reimbursed clinical testing. The CMS estimates these cuts will save taxpayers approximately $1 billion annually.
Investing.com - Medicare has been overpaying laboratories by roughly 16% compared with private insurers, the Centers for Medicare & Medicaid Services disclosed Monday, and it intends to close that gap through annual reimbursement cuts of up to 15% beginning January 1, 2027.
CMS released preliminary Calendar Year 2027 Clinical Laboratory Fee Schedule rates on September 21, 2026, estimating the realignment will save taxpayers approximately $1 billion annually, according to the agency's press release. Quest Diagnostics (NYSE: DGX) and Labcorp (NYSE: LH), which both derive a substantial portion of revenue from routine clinical testing reimbursed directly under the CLFS, are the most direct equity expressions of that rate reset — and Monday's announcement frames the clearest earnings risk either company has faced from Medicare in years.
CMS Administrator Dr. Mehmet Oz framed the move as an overdue correction. "Taxpayers and Medicare patients have been paying excessive rates to labs for years, but with some help from Congress, CMS is working to ensure that Medicare isn't paying more than private insurers for the exact same tests," he said in Monday's press release. The preliminary rates were drawn from data reported by 6,411 laboratories during a 2026 reporting period, according to CMS — a far broader sample than the prior implementation round under the Protecting Access to Medicare Act, which collected data from less than 1% of laboratories and ultimately cut nearly $4 billion from CLFS payments between 2018 and 2020.
By statute, CLFS payment rates cannot be reduced by more than 15% per year through 2029, meaning the full realignment will be phased in gradually rather than applied at once. Even so, the compounding math is significant: a 15% cut in 2027, followed by further reductions of up to 15% in both 2028 and 2029, would represent a substantial cumulative reduction in Medicare reimbursement for routine testing. Neither DGX nor LH has publicly disclosed what share of total revenue flows through CLFS-reimbursed routine tests versus advanced or proprietary diagnostics, which follow a different rate-setting path; that ratio is the critical number for sizing the earnings impact, and analysts have not yet published revised EPS estimates based on Monday's data.
Quest Diagnostics moved ahead of the CMS release with a political offensive. The company commissioned a national survey, published September 16, 2026 via PR Newswire, showing nine in ten voters expressed concern that the cuts would harm patient access to diagnostic testing. Quest and the American Clinical Laboratory Association are lobbying Congress to pass the RESULTS Act, a bipartisan bill with approximately 130 sponsors and backing from more than 70 patient advocacy groups, before January 2027. "For many dangerous health conditions, laboratory insights are the only tool available to identify disease risks in early, preventable stages," said Dr. Lee H. Hilborne, Senior National Medical Director at Quest Diagnostics, in the survey release. "When access to reliable, innovative testing is at risk, they and their families are the ones who will pay the price."
The RESULTS Act's passage remains uncertain, and without congressional intervention the rate cuts will take effect automatically once CMS finalizes the schedule. Labs and advocacy groups have approximately 30 days from September 21 to submit formal comments on the preliminary rates, with the public comment window closing around October 21, 2026. Whether DGX, LH, or the ACLA plan written submissions during that window has not been publicly confirmed.
Final CY 2027 CLFS payment rates are scheduled for publication by CMS in November 2026, at which point the revenue impact for both companies will be locked in for the January 1, 2027 effective date. That November release is the next concrete catalyst: if final rates mirror the preliminary schedule, consensus EPS estimates for DGX and LH will need to reflect the full 15% first-year cut on their CLFS-exposed revenue lines. Based on Medicare revenue share disclosed in each company's most recent annual report, analysts estimate that every 5-percentage-point reduction in CLFS rates translates to a roughly 1–2% EPS headwind for DGX and a comparable drag for LH; since the full 15% first-year reduction spans three such 5-point tranches, the implied first-year EPS drag is approximately 3–6% for both DGX and LH before any volume or mix offsets. Precise sell-side revisions tied to Monday's preliminary data are pending and are expected to begin circulating after November finalization. If congressional action on the RESULTS Act advances before then, it could blunt or delay the cuts, but with fewer than 15 legislative working days likely available before year-end, the window for relief is narrow and the default scenario remains the full reduction taking effect in Q1 2027.